FDA Shortage List and Compounded GLP-1s: What Patients Need to Know in 2025

What the FDA Drug Shortage List Actually Does

The FDA drug shortage database is a publicly maintained registry of medically necessary drugs that face supply disruptions serious enough to affect patient care. Its legal significance goes beyond inconvenience tracking. Under Section 503B of the Food, Drug, and Cosmetic Act, outsourcing facilities are allowed to compound copies of FDA-approved drugs without individual prescriptions only when those drugs appear on an FDA-recognized shortage list. Once a drug leaves that list, the statutory basis for high-volume compounding collapses.

The FDA's shortage database is searchable at fda.gov. Semaglutide injection (the active ingredient in Ozempic and Wegovy) entered shortage status in 2022 as demand from both diabetes and weight management prescriptions outpaced Novo Nordisk's manufacturing capacity. Tirzepatide injection (Mounjaro, Zepbound) followed a similar trajectory. During the peak shortage window from 2022 through 2024, the FDA estimated that hundreds of 503B outsourcing facilities were producing compounded semaglutide and tirzepatide, and independent surveys suggested more than one million Americans were using compounded versions of these drugs at various points in that period.

The legal machinery changed when FDA resolved both shortages. Tirzepatide was removed in October 2024. Semaglutide was removed in February 2025. Each removal came with a compliance period for 503B facilities to wind down production, but those wind-downs have now concluded. Patients who were receiving compounded GLP-1s from a 503B facility and have not transitioned to a brand product or a legitimate 503A prescription are in a legally and medically ambiguous situation.

How 503A and 503B Compounding Differ

The distinction between 503A and 503B is not semantic. It determines who can compound, in what quantities, and under what oversight rules.

503A pharmacies are traditional compounding pharmacies. They prepare medications based on a valid, patient-specific prescription from a licensed prescriber. They are regulated primarily by state boards of pharmacy, not by the FDA in the same manner as drug manufacturers. 503A pharmacies cannot sell compounded drugs to patients without a prescription, cannot produce large batch quantities for general distribution, and are subject to current Good Manufacturing Practice (cGMP) requirements only in a limited sense. The FDA's guidance on 503A compounding is available at fda.gov.

503B outsourcing facilities operate under heavier federal oversight. They register with the FDA, are subject to cGMP inspections, and may compound drugs in large batches without patient-specific prescriptions, provided those drugs appear on the FDA shortage list or on the agency's list of drugs that present a clinical need. When semaglutide and tirzepatide were on the shortage list, 503B facilities could legally produce bulk compounded versions. When the drugs came off the list, 503B facilities lost that legal basis entirely.

A 503A pharmacy may still compound semaglutide or tirzepatide today under the following conditions: a licensed prescriber has determined that the FDA-approved commercial product does not meet a specific patient's clinical need (for example, a dose not commercially available, a required excipient change for a documented allergy, or a supply gap at the patient's local dispensing point). That determination must be documented and the prescription must be genuinely patient-specific. Blanket prescriptions generated by telehealth platforms purely to route around commercial pricing do not meet the legal standard.

The Semaglutide Shortage: Timeline and Resolution

Semaglutide's path through the shortage list is worth tracing precisely because the timeline affects what compounding was legal and when.

Novo Nordisk first reported supply constraints for Ozempic (semaglutide 0.5 mg, 1 mg) in 2022. The FDA added semaglutide to its shortage database, opening the door for 503B compounding. Wegovy (semaglutide 2.4 mg) had its own supply disruptions, prompting a separate shortage designation. During this period, compounded semaglutide from 503B facilities was legal and widely dispensed through telehealth platforms.

STEP-1 (N=1,961) demonstrated that semaglutide 2.4 mg produced 14.9% mean body weight reduction at 68 weeks versus 2.4% with placebo (P<0.001) [1]. STEP-3 (N=611) showed that combining semaglutide 2.4 mg with intensive behavioral therapy produced a mean weight loss of 16.0% at 68 weeks versus 5.7% with intensive behavioral therapy alone [3]. Those data drove enormous prescriber and patient interest, straining supply further. By late 2023 and into 2024, Novo Nordisk had expanded manufacturing capacity substantially. The FDA determined that supply was adequate to meet demand and removed semaglutide from shortage status in February 2025. The Wegovy FDA label reflects current approved dosing: 0.25 mg weekly escalating to 2.4 mg weekly over 16 to 20 weeks [9].

The Tirzepatide Shortage: Timeline and Resolution

Tirzepatide (Mounjaro for type 2 diabetes, Zepbound for obesity) was added to the FDA shortage list in 2023. The clinical demand was substantial. SURMOUNT-1 (N=2,539) showed that tirzepatide 15 mg produced a mean weight reduction of 22.5% at 72 weeks versus 2.4% with placebo (P<0.001) [5]. SURMOUNT-2 in patients with type 2 diabetes showed 15.7% weight loss at 72 weeks with tirzepatide 15 mg [6]. SURMOUNT-4 found that patients who discontinued tirzepatide after 36 weeks of treatment regained approximately 14 percentage points of lost weight by week 88, underscoring the need for continued access [8].

Eli Lilly expanded production, and the FDA removed tirzepatide from the shortage list in October 2024. A compliance period allowed 503B facilities to wind down. The Zepbound FDA label documents approved tirzepatide dosing for chronic weight management: 2.5 mg weekly escalating to 5 mg, 10 mg, or 15 mg based on tolerability [10].

Compounded vs. Brand GLP-1s: What the Safety Evidence Actually Shows

Neither the FDA nor any independent clinical trial has conducted a head-to-head randomized comparison of compounded versus brand-name semaglutide or tirzepatide in humans. That absence of data is itself a safety signal patients should register.

Brand-name Wegovy and Zepbound contain the active drug as the free-base peptide, formulated with specific excipients that have been validated for stability, bioavailability, and injection tolerability through the FDA's New Drug Application (NDA) review process. The FDA has documented a distinct safety concern with compounded versions: some 503A and unregistered pharmacies have used semaglutide sodium or semaglutide acetate salts rather than the base form of semaglutide [see FDA communications at fda.gov]. Salt forms are not FDA-approved, differ in molecular weight, and have unknown pharmacokinetics in humans. The FDA has received adverse event reports associated with compounded semaglutide products including dosing errors, nausea, vomiting, and hospitalization.

The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% over a median 34.2 months in patients with pre-existing cardiovascular disease (hazard ratio 0.80; 95% CI 0.72 to 0.90) [4]. That cardiovascular benefit was established with Wegovy specifically. Whether a compounded formulation using a different salt form or different excipients would replicate that outcome is not known.

The AACE/ACE obesity clinical practice guidelines state that pharmacotherapy for obesity should use agents with demonstrated efficacy and safety through rigorous clinical trial data [11]. Compounded products that have not undergone the same testing cannot claim equivalence to trial-studied drugs by that standard.

One area where compounded products have historically offered a real clinical advantage is dose titration flexibility. Patients who experience significant gastrointestinal side effects at standard commercial doses have sometimes benefited from a slower titration schedule using doses not available in commercial pen configurations. That remains a legitimate clinical reason for 503A compounding when documented by a prescriber.

How to Verify a Compounding Pharmacy

Patients using or considering compounded GLP-1 medications should verify pharmacy legitimacy through two independent checks.

First, search the FDA's drug establishment registration and listing database, available at fda.gov. A 503B outsourcing facility must be registered with the FDA. Its registration number and inspection history are public. An unregistered pharmacy cannot legally operate as a 503B facility, regardless of what it claims on its website.

Second, confirm licensure with the relevant state board of pharmacy. Every 503A compounding pharmacy must hold a valid state pharmacy license in the state where it operates and, in most cases, in the state where the patient receiving the medication resides. The National Association of Boards of Pharmacy maintains a directory of state boards at nabp.pharmacy. Pharmacies that are not listed or that cannot provide a verifiable license number should be avoided entirely.

Red flags that indicate a pharmacy is operating outside legal bounds include: no requirement for a prescription from a licensed US prescriber, offering "research grade" or "not for human use" peptide versions of semaglutide or tirzepatide, shipping from outside the United States, advertising unlimited quantity without medical supervision, and claiming the product is "FDA approved" when compounded drugs are not.

"Patients should ask their compounding pharmacy for documentation of its PCAB accreditation or 503B registration before filling any prescription," according to guidance from the FDA's Human Drug Compounding page. PCAB (Pharmacy Compounding Accreditation Board) accreditation is a voluntary quality standard, but its presence is a meaningful signal. Its absence is not disqualifying, but absence of both PCAB and FDA registration in a pharmacy claiming 503B status is a serious warning sign.

What Patients Currently on Compounded GLP-1s Should Do

The practical steps for patients differ depending on their current situation.

Patients receiving compounded tirzepatide from a 503B facility should have already transitioned or should transition now. The legal window for 503B tirzepatide compounding closed following the October 2024 shortage resolution. Patients receiving compounded semaglutide from a 503B facility face the same situation following the February 2025 resolution.

Patients receiving a patient-specific 503A compounded GLP-1 should ask their prescriber to document the specific clinical justification in writing. If the justification is only cost, that does not meet the regulatory standard for 503A compounding post-shortage. If the justification is a documented clinical need (specific dose, allergy to excipient, genuine supply gap), the prescription may be defensible, but the patient and prescriber share responsibility for confirming the dispensing pharmacy holds appropriate state licensure.

Patients who want to transition to brand-name Wegovy or Zepbound should discuss coverage options with their prescriber. Both manufacturers run patient assistance programs. Novo Nordisk's NovoCare program and Eli Lilly's LillyCaresFoundation offer reduced-cost access for qualifying patients. Insurance coverage for Wegovy and Zepbound has expanded since 2023, particularly following changes to Medicare Part D rules for anti-obesity medications.

STEP-5 (N=304) showed that semaglutide 2.4 mg continued to produce weight loss benefits over 104 weeks with a mean reduction of 15.2% from baseline, compared to 2.6% regain in the placebo group (P<0.001) [2]. Long-term therapy with a stable, verified formulation is the clinical goal. Switching from compounded to brand does not restart the clock on efficacy. Patients who have responded to compounded semaglutide and transition to Wegovy should expect to continue their response if dosing is maintained consistently.

The Regulatory Outlook for 2025 and Beyond

The FDA has been direct about its enforcement posture. In 2025 warning letters and public communications, the agency has targeted: pharmacies using unapproved salt forms of semaglutide, vendors marketing peptides labeled "not for human use" that are functionally identical to prescription GLP-1 drugs, and international online pharmacies shipping compounded GLP-1s without a valid US prescription.

The agency has not banned 503A compounding of semaglutide or tirzepatide outright. Enforcement has focused on bad actors rather than on the 503A pathway itself. Patients and prescribers operating within legitimate 503A frameworks, with proper documentation and a licensed pharmacy, face a different risk profile than those purchasing from unverified online sources.

One regulatory development worth watching: the FDA is reviewing whether to add specific GLP-1 formulations to the Difficult to Compound list, which would further restrict 503A compounding. A final decision on that question had not been published as of this article's review date. Patients should check fda.gov/drugs/human-drug-compounding for updates.

STEP-8 (N=338) compared semaglutide 2.4 mg directly against liraglutide 3 mg over 68 weeks and found semaglutide produced 15.8% mean weight loss versus 6.4% with liraglutide [7]. That head-to-head datum shows that drug identity and formulation specifics matter for outcomes. A compounded product that deviates from the validated formulation of the trial drug may not replicate the trial result.

Patients who require weight management therapy now have two FDA-approved, commercially available options in Wegovy and Zepbound. SURMOUNT-3 (N=579) demonstrated that tirzepatide 10 mg or 15 mg after a lead-in of intensive lifestyle intervention produced an additional 18.4% weight loss from the post-lead-in baseline [7b]. These drugs work. Access through verified, approved channels remains the most defensible path forward.

Ask your prescriber to confirm whether your current GLP-1 source holds active FDA 503B registration or a documented 503A patient-specific justification, and request the pharmacy's state license number before your next fill.